Fate Therapeutics shares Phase 1 FT819 data for lupus nephritis

Mon, 26 Oct 2026 07:02:16 -0400

Fate Therapeutics, Inc. (NASDAQ: FATE) presented updated Phase 1 clinical data for its off-the-shelf CAR T-cell candidate FT819 in patients with systemic lupus erythematosus (SLE) with lupus nephritis (LN) at the American Society of Nephrology Kidney Week 2026 in Denver, Colorado.

The oral presentation, delivered Oct. 24 by Dr. Jonathan Graf of the University of California, San Francisco, reported data from the ongoing Phase 1 FT819-102 study as of an Aug. 18, 2026 data cutoff.

Among active LN patients treated with FT819 plus bendamustine conditioning — the regimen selected for the company's ongoing Phase 2 RECLAIM-LN study — all patients evaluable at

Fate Therapeutics shares Phase 1 FT819 data for lupus nephritis

Mon, 26 Oct 2026 07:02:16 -0400

Among active LN patients treated with FT819 plus bendamustine conditioning — the regimen selected for the company's ongoing Phase 2 RECLAIM-LN study — all patients evaluable at

Fate Therapeutics shares Phase 1 FT819 data for lupus nephritis

Mon, 26 Oct 2026 07:02:16 -0400

Among active LN patients treated with FT819 plus bendamustine conditioning — the regimen selected for the company's ongoing Phase 2 RECLAIM-LN study — all patients evaluable at

Fate Therapeutics Presents Updated Preliminary Data for FT819 in Active Lupus Nephritis at American Society of Nephrology Kidney Week 2026

Mon, 26 Oct 2026 07:00:00 -0400

Active LN patients in the Phase 1 study treated with FT819 and the less-intensive conditioning (bendamustine) regimen selected for the RECLAIM-LN study achieved 100% renal response at Month 6, with approximately 50% mean reduction in proteinuria

Encouraging safety profile with no dose-limiting toxicities, high-grade CRS, ICANS, GvHD or IEC-HS in autoimmune patients treated with a single dose of FT819; low incidences of infection and cytopenia were also observed

Clinical data reinforces the patient value of the ongoing RECLAIM-LN, a Phase 2 potentially registrational study of FT819 in refractory, moderate-to-severe SLE with LN

Fate Therapeutics Presents Updated Preliminary Data for FT819 in Active Lupus Nephritis at American Society of Nephrology Kidney Week 2026

Mon, 26 Oct 2026 07:00:00 -0400

Clinical data reinforces the patient value of the ongoing RECLAIM-LN, a Phase 2 potentially registrational study of FT819 in refractory, moderate-to-severe SLE with LN

Fate Therapeutics names Jamie Harrell SVP of commercial operations

Mon, 12 Oct 2026 07:00:28 -0400

Fate Therapeutics, Inc. (NASDAQ: FATE) appointed Jamie Harrell as Senior Vice President of Market Development and Commercial Operations, effective Oct. 12, 2026, according to a press release from the San Diego-based company.

Harrell will lead commercial and market development strategy across Fate's autoimmunity and oncology programs. His responsibilities include overseeing commercialization efforts tied to FT819, which is being evaluated in RECLAIM-LN, a Phase 2 trial in refractory lupus nephritis, and FT839, which is in a Phase 1/2 trial across multiple autoimmune indications including rheumatoid arthritis.

Harrell brings more than 25 years of commercial experience. He most recently served as Vice President of

Fate Therapeutics names Jamie Harrell as commercial operations chief

Mon, 12 Oct 2026 07:00:15 -0400

Fate Therapeutics, Inc. (NASDAQ: FATE) has appointed Jamie Harrell as Senior Vice President of Market Development and Commercial Operations, effective October 12, 2026, according to a company statement.

Harrell, who brings more than 25 years of commercial leadership experience, will oversee commercial and market development strategy across the San Diego-based company's autoimmunity and oncology programs. His responsibilities include developing physician engagement strategy and expanding access to the company's off-the-shelf CAR T-cell therapies in outpatient and community settings.

The role was newly created to support Fate Therapeutics as it advances its pipeline toward commercialization, including FT819, which is being evaluated in RECLAIM-LN, a

Fate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-cell Therapies

Mon, 12 Oct 2026 07:00:00 -0400

Commercial leader brings lupus nephritis and first-in-class launch experience as FT819 advances in the RECLAIM-LN Phase 2 trial

Proven record in advancing breakthrough autoimmune therapies and establishing novel lupus treatments in community settings

SAN DIEGO, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative and broadly accessible pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced the appointment of Jamie Harrell to its executive leadership team, effective October 12, 2026.

Mr.

Fate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-cell Therapies

Mon, 12 Oct 2026 07:00:00 -0400

Commercial leader brings lupus nephritis and first-in-class launch experience as FT819 advances in the RECLAIM-LN Phase 2 trial

Proven record in advancing breakthrough autoimmune therapies and establishing novel lupus treatments in community settings

Mr.

Fate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-cell Therapies

Mon, 12 Oct 2026 07:00:00 -0400

Commercial leader brings lupus nephritis and first-in-class launch experience as FT819 advances in the RECLAIM-LN Phase 2 trial

Proven record in advancing breakthrough autoimmune therapies and establishing novel lupus treatments in community settings

Mr.

Fate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-cell Therapies

Mon, 12 Oct 2026 07:00:00 -0400

Commercial leader brings lupus nephritis and first-in-class launch experience as FT819 advances in the RECLAIM-LN Phase 2 trial

Proven record in advancing breakthrough autoimmune therapies and establishing novel lupus treatments in community settings

Mr.

Entera Bio adds former Gilead executive Laura Hamill to its board

Tue, 06 Oct 2026 08:00:50 -0400

Entera Bio Ltd. (NASDAQ: ENTX) announced the appointment of Laura Hamill to its Board of Directors, effective December 1, 2026. Hamill succeeds Yonatan Malca, who is stepping down after 16 years of service.

Hamill brings more than 35 years of biopharmaceutical commercial leadership experience. Most recently, she served as Executive Vice President of Worldwide Commercial Operations at Gilead Sciences, where she led an organization of approximately 2,500 employees responsible for $22 billion in annual revenue.

Prior to Gilead, Hamill spent nearly two decades at Amgen in roles of increasing scope, including Senior Vice President of U.S. Commercial Business Operations, where she oversaw

Entera Bio adds former Gilead executive Laura Hamill to its board

Tue, 06 Oct 2026 08:00:50 -0400

Prior to Gilead, Hamill spent nearly two decades at Amgen in roles of increasing scope, including Senior Vice President of U.S. Commercial Business Operations, where she oversaw

Entera Bio adds former Gilead executive Laura Hamill to its board

Tue, 06 Oct 2026 08:00:50 -0400

Prior to Gilead, Hamill spent nearly two decades at Amgen in roles of increasing scope, including Senior Vice President of U.S. Commercial Business Operations, where she oversaw

Entera Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial Expertise

Tue, 06 Oct 2026 08:00:00 -0400